{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:38:08Z","timestamp":1792892288354,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cllc.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:20:50Z","timestamp":1772036450000},"page":"41-46.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States"],"prefix":"10.1016","volume":"27","author":[{"given":"Xiuning","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Easson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Bellefleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soetkin","family":"Vlassak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur A.","family":"Dashputre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.02.004_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cllc.2026.02.004_bib0002","unstructured":"American Cancer Society. Cancer facts & figures 2025. Accessed: September 30, 2025. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf."},{"issue":"10212","key":"10.1016\/j.cllc.2026.02.004_bib0003","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.cllc.2026.02.004_bib0004","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cllc.2026.02.004_bib0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.004_bib0006","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for small cell lung cancer V.2.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed: September 17, 2025. Available at: NCCN.org."},{"key":"10.1016\/j.cllc.2026.02.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104616","article-title":"The emerging landscape and future perspective of SCLC transformation: from molecular mechanisms to therapeutic strategies","volume":"207","author":"Zhang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2026.02.004_bib0008","article-title":"Validation of an updated algorithm to identify patients with incident non-small cell lung cancer in administrative claims databases","volume":"8","author":"Patel","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.cllc.2026.02.004_bib0009","series-title":"Patient characteristics and treatment patterns in extensive stage small cell lung cancer (ES-SCLC)","author":"Iams","year":"2025"},{"key":"10.1016\/j.cllc.2026.02.004_bib0010","series-title":"Real-world treatment patterns in ES-SCLC highlight continued unmet medical need in the era of new therapies: ESSENCE study","author":"Halmos","year":"2025"},{"issue":"12","key":"10.1016\/j.cllc.2026.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","article-title":"Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer","volume":"29","author":"Shaw","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2026.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/CLEP.S546282","article-title":"A multi-country study of the clinical course of extensive-stage small cell lung cancer: a six-study analysis of real-world treatment patterns and outcomes","volume":"17","author":"Pundole","year":"2025","journal-title":"Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.cllc.2026.02.004_bib0013","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/crj.13188","article-title":"Analysis of clinical features and prognostic factors of lung cancer patients: a population-based cohort study","volume":"14","author":"Gao","year":"2020","journal-title":"Clin Respir J"},{"issue":"2","key":"10.1016\/j.cllc.2026.02.004_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00432-024-05621-9","article-title":"Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities","volume":"150","author":"Wu","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115592","article-title":"Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: a multicentric retrospective analysis","volume":"225","author":"Monaca","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:50:24Z","timestamp":1778817024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525730426000306"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}